Lexiscan (Regadenoson) Patent Expiration, LOE Window & CMS Spending

Lexiscan (Regadenoson) by Astellas Pharma: FDA Orange Book core substance LOE 2027-02-02, 0 AB generics, $12.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstellas Pharma
FDA Application & PathwayN022161 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE Date2027-02-02
Last Listed Patent or Exclusivity Date2027-02-02
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$12.8M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$12.8M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.